BIOMARKERS IN THE SELECTION OF THERAPY OF HEART FAILURE

• Main Authors: BLOCK, Dirk, ZAUGG, Christian, KRAUSE, Friedemann, MODEL, Fabian, WIENHUES-THELEN, Ursula-Henrike, BRUNNER, Hans-Peter, ROLNY, Vincent
• Format: Patent
• Language: English; French; German
• Published: 14.10.2015
• Subjects: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; PHYSICS; TESTING

The present application relates to a method for identifying a subject being eligible to the administration of at least one medicament selected from the group consisting of a beta blocker, an aldosterone antagonist, a diuretic, and an inhibitor of the renin-angiotensin system. The method is based on the determination of the amount of at least one biomarker selected from the group consisting of GDF-15 (Growth Differentiation Factor 15), endostatin, mimecan, IGFBP7 (IGF binding protein 7), a cardiac Troponin, a BNP-type peptide, uric acid, Gal3 (Galectin-3), osteopontin, sST2 (soluble ST2), P1GF, sFlt-1, P1NP, Cystatin C, Prealbumin, and Transferrin in a sample from a subject suffering from heart failure. Further, the method comprises the step of comparing the, thus, determined amount with a reference amount. Further envisaged by the present application are kits and devices adapted to carry out the method of the present application. The present application also relates to a system for identifying a subject being eligible to the administration of at least one medicament as disclosed herein and to reagents and kits used in performing the methods as disclosed herein. The present application concerns more specifically the marker / medicament combination Cystatin C / aldosterone antagonist.